InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Two key appointments to bolster PharmAust vet drug programs 3 Oct 2017 9:58AM $0.050 $0.230 risen by 360%
- Reformulation project achieves first milestones and on-track 20 Sep 2017 9:06AM $0.059 $0.230 risen by 289.83%
- PharmAust secures core Europe patent 12 Sep 2017 8:20AM $0.059 $0.230 risen by 289.83%
- PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement 4 Sep 2017 8:24AM $0.062 $0.230 risen by 270.97%
- Appendix 4G & Corporate Governance Statement 1 Sep 2017 8:47AM $0.062 $0.230 risen by 270.97%
- Appendix 4E & Full Year Statutory Accounts 2017 1 Sep 2017 8:21AM $0.062 $0.230 risen by 270.97%
- PharmAust Investor Presentation 30 Aug 2017 9:16AM $0.064 $0.230 risen by 259.38%
- PharmAust Shareholders Update 22 Aug 2017 9:12AM $0.065 $0.230 risen by 253.85%
- Appendix 4C - Quarterly Report & Brief Company Update 1 Aug 2017 8:19AM $0.071 $0.230 risen by 223.94%
- Epichem reports record $3m revenues & expands laboratory 17 Jul 2017 8:22AM $0.073 $0.230 risen by 215.07%
- Canadian-based specialists to reformulate monepantel 27 Jun 2017 9:55AM $0.065 $0.230 risen by 253.85%
- New European patent granted for non-cancer applications 8 Jun 2017 8:25AM $0.079 $0.230 risen by 191.14%
- PharmAust secures core patent in Japan 6 Jun 2017 8:24AM $0.081 $0.230 risen by 183.95%
- PharmAust Shareholders Update and Roadmap 30 May 2017 8:30AM $0.085 $0.230 risen by 170.59%
- PharmAust Investor Presentation - May 2017 22 May 2017 9:42AM $0.071 $0.230 risen by 223.94%
- Phase II trial prelim results demonstrate clinical benefit 19 May 2017 8:22AM $0.069 $0.230 risen by 233.33%
- New patent granted for non-cancer applications 17 May 2017 8:21AM $0.072 $0.230 risen by 219.44%
- PharmAust secures core China patent 5 May 2017 8:29AM $0.055 $0.230 risen by 318.18%
- Appendix 4C - Quarterly Report & Company Update - March 2017 13 Apr 2017 1:31PM $0.052 $0.230 risen by 342.31%
- Dr Richard Mollard appointed as Chief Scientific Officer 8 Mar 2017 8:26AM $0.053 $0.230 risen by 333.96%
- PharmAust raises a further $534k 3 Mar 2017 8:16PM $0.050 $0.230 risen by 360%
- Dr Richard Hopkins Appointed as CEO of PharmAust 1 Mar 2017 8:14AM $0.048 $0.230 risen by 379.17%
- Appendix 4D & Financial Report - Dec 2016 28 Feb 2017 6:01PM $0.048 $0.230 risen by 379.17%
- Appendix 4C - Quarterly Report & Company Update 31 Jan 2017 4:27PM $0.051 $0.230 risen by 350.98%
- PharmAust Receives $406K R&D Rebate from ATO 30 Jan 2017 2:00PM $0.052 $0.230 risen by 342.31%

501 - 525 of 796 results

Page 21 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.